From Lab to Bedside: Discoveries in the Lab that are Changing Clinical Care
Hie-Won L. Hann, MD, FAASLD (in collaboration with Dr. Su at Baruch S.Blumberg Institute).
For liver cancer, early detection of a small tumor provides the highest rate of survival. Currently, an abdominal MRI is the best method of detection. A blood test, alpha fetoprotein (AFP), detects about 40-60% of the tumor. Liver cancer cells contain “cancer associated mutated or methylated DNAs.” These liver cancer associated DNAs (LCa-DNAs) can be released into circulation as cells die and the fragmented cells are filtered through the kidneys and excreted into the urine. Dr. Su and her colleagues developed a urine test for LCa-DNAs. This testing allows for earlier detection of liver cancer and will make detection more accessible for patients as a simple urine sample may be gathered at a primary care or satellite facility.
The urine test could be used for screening and effective management of primary and recurrent liver cancer.
This work was presented at the AASLD meeting November, 2015 as a poster.
Full manuscript is in preparation.
Ali A. Siddiqui MD FASGE FACP
This is a large study in which a new stent called AXIOS is used to drain fluid collections around the pancreas. It demonstrated that the newly released AXIOS stent allows us to drain fluid collections around the pancreas by endoscopic means with excellent clinical success. The AXIOS stent was also extremely safe to use with few complications. Additionally, this study also shows that we can spare patients from undergoing surgery and safely perform this procedure in less than an hour.
This work was presented at the DDW meeting May, 2015
Click here to view all of Jefferson's current Gastroenterology & Hepatology clinical trials.